General Information of Drug (ID: DMB7CPG)

Drug Name
Elsiglutide Drug Info
Synonyms Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma
Indication
Disease Entry ICD 11 Status REF
Diarrhea ME05.1 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMB7CPG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teduglutide DMYOAKS Short bowel syndrome KB89.1 Approved [3]
SAN-134 DMWU71N Osteoporosis FB83.0 Phase 1 [4]
ZP-1848 DMGTL8Z Inflammatory bowel disease DD72 Phase 1 [5]
FE-203799 DMBX81R Gastrointestinal disease DE2Z Investigative [6]
AMX-256 DMGHXQE Short bowel syndrome KB89.1 Investigative [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 2 receptor (GLP2R) TT1YWO5 GLP2R_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01543451) Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea. U.S. National Institutes of Health.
2 Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865)
5 US patent application no. 8,580,918, Peptidic glp-2 agonists.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250).